Clopidogrel and CYP2C19: Pharmacogenetic Testing Ready for Clinical Prime Time?
For patients with acute coronary syndrome who have undergone interventions such as placement of a stent, it has become standard practice to treat them with a combination of aspirin and opidogrel to prevent subsequent thrombotic events; however, clopidogrel is a drug that requires activation by a liver enzyme, CYP2C19.
More description
For patients with acute coronary syndrome who have undergone interventions such as placement of a stent, it has become standard practice to treat them with a combination of aspirin and opidogrel to prevent subsequent thrombotic events; however, clopidogrel is a drug that requires activation by a liver enzyme, CYP2C19.
2015-10-08
11 min
Listen elsewhere
Available Results
Generated results are saved to your library for reuse and search.
No generated results are available for this episode yet.
Transcript
No transcript is available for this episode yet.
Sign in to generate a transcript for review.
Sign in
Chapters
No chapters available.